Table 2.
Gene | Cancer | Observed connections with hypermethylation | References |
---|---|---|---|
SALL3 | HNSCC | No data related to gene expression | Chaisaingmongkol et al. (2012) |
FANCB | HNSCC | No data related to gene expression | Chaisaingmongkol et al. (2012) |
NEIL1 | HNSCC | Lower gene expression | Chaisaingmongkol et al. (2012) |
AGTR1 | OSCC | Association with OSCC development | Foy et al. (2015) |
FOXI2 | OSCC | Association with OSCC development | Foy et al. (2015) |
PENK | OSCC | Association with OSCC development | Foy et al. (2015) |
LXN | OSCC | Downregulation of gene expression | Basu et al. (2017) |
HLA-DPB1 | OSCC | Upregulation of gene expression | Basu et al. (2017) |
ZNF577 | OSCC | Downregulation of gene expression | Basu et al. (2017) |
ZNF154 | OSCC | Downregulation of gene expression | Basu et al. (2017) |
CTDSP1 | OSCC | Downregulation of gene expression | Basu et al. (2017) |
ZSCAN31 | OSCC | Not significant downregulation of gene expression | Basu et al. (2017) |
LDLRAD4 | OSCC | Not significant downregulation of gene expression | Basu et al. (2017) |
NDN | HNSCC | Association with overall survival time | Virani et al. (2015) |
CD1A | HNSCC | Association with overall survival time | Virani et al. (2015) |
GRIM-19 | HNSCC | Significant independent risk factor for HNSCC, and Not significant downregulation of gene expression | Zhang et al. (2015b) |
PTEN | NPC | Downregulation of gene expression | Li et al. (2014a) |
OSCC | No data related to gene expression | Sushma et al. (2016) | |
PAX1 | HNSCC | Downregulation of gene expression | Guerrero-Preston et al. (2014); |
OSCC | No data related to gene expression | Morandi et al. (2017) | |
PAX5 | HNSCC | Downregulation of gene expression | Guerrero-Preston et al. (2014) |
ZIC4 | HNSCC | No data related to gene expression | Guerrero-Preston et al. (2014) |
PLCB1 | HNSCC | No data related to gene expression | Guerrero-Preston et al. (2014) |
LRPPRC | TSCC | No data related to gene expression | Bhat et al. (2017) |
RAB6C | TSCC | Downregulation of gene expression | Bhat et al. (2017) |
ZNF471 | TSCC | Downregulation of gene expression | Bhat et al. (2017) |
MINT1 | HNSCC | No data related to gene expression | Choudhury and Ghosh (2015) |
MINT2 | HNSCC | No data related to gene expression | Choudhury and Ghosh (2015) |
MINT31 | HNSCC | No data related to gene expression | Choudhury and Ghosh (2015) |
TFPI2 | OSCC | Downregulation of protein expression | Kim et al. (2019) |
SOX17 | OSCC |
Downregulation of protein expression Association with overall survival time |
Kim et al. (2019) |
GATA4 | OSCC |
Downregulation of protein expression Association with overall survival time |
Kim et al. (2019) |
ESRRG | LSCC | Association with overall survival time | Shen et al. (2019) |
HOXA9 | HNSCC | Possible association with progression and Metastasis of HNSCC | Zhou et al. (2019) |
ZNF671 | HNSCC |
Downregulation of gene and protein expression Association with overall survival time |
Zhang et al. (2019) |
RHCG | HNSCC |
Downregulation of gene expression Association with overall survival time |
Xu et al. (2019) |
SALL1 | HNSCC |
Downregulation of gene expression Association with risk of disease recurrence |
Misawa et al. (2018b) |
CEACAM6 | LSCC | Downregulation of gene expression | Bednarek et al. (2018) |
PCDH17 | LSCC | Downregulation of gene expression | Byzia et al. (2018) |
CPEB4 | HNSC | Downregulation of gene and protein expression | Zeng et al. (2018) |
CLDN11 | LSCC | Associated with lymph node metastasis, advanced clinical stage, and higher T classification | Shen et al. (2017) |
SLIT2 | HNSC | Associated with tumor location | Alsofyani et al. (2017) |
KL | HNSC | Associated with high grade tumor | Alsofyani et al. (2017) |
SFRP1 | HNSCC | Association with poor survival for patients with moderately differentiated tumor (grade 2) | Alsofyani et al. (2017) |
PTPRD | LSCC | Downregulation of gene expression | Szaumkessel et al. (2017) |